ASL di Salerno - PO Andrea tortora

The research program at ASL di Salerno focuses on blood‑related cancers, notably Follicular Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, aiming to refine treatment intensity and improve patient outcomes.

• Optimizing chemotherapy cycles for high‑burden follicular lymphoma
• Evaluating novel combination regimens in relapsed/refractory CLL/SLL
• Assessing progression‑free survival benefits of tailored immunochemotherapy

These studies seek to determine whether reduced chemotherapy exposure can maintain effectiveness while lessening side effects, and to compare emerging drug combinations against established standards.

In the neoplasm portfolio, the site investigates Acute Myeloid Leukemia with a focus on patients carrying the NPM1 mutation who cannot receive intensive chemotherapy, testing targeted agents alongside existing therapies.

• Assessing the impact of adding revumenib to azacitidine and venetoclax
• Exploring survival improvements for newly diagnosed NPM1‑mutated AML
• Providing less‑intensive treatment options for high‑risk patients

The goal is to enhance overall survival and remission rates by integrating precision‑medicine approaches into standard care pathways.